guttitude logo

guttitude

early access
Get Checklistguttitude Pro
← Back to atlas
fulltoplow inflation risk

Eubacterium hallii

type 2 diabetes

Eubacterium hallii looks like a credible signal in type 2 diabetes, though some caution is still warranted.

Eubacterium hallii shows a strong literature footprint in type 2 diabetes, with substantial central evidence and broader supporting literature.

eubacterium_hallii
Credibility score
61
Human translation
3/5
Reproducibility
4/5
Novelty
3/5
Actionability
4/5
Credibility 61Human translation 3/5Reproducibility 4/5Novelty 3/5Actionability 4/5
Why this scores the way it does
  • strong central evidence base
  • meaningful supporting human literature
  • substantial preclinical support
Main caveats
  • directionality and confounding still require curated review

Primary central evidence

19 papers
Gut Microbiota in Type 2 Diabetes Individuals and Correlation with Monocyte Chemoattractant Protein1 and Interferon Gamma from Patients Attending a Tertiary Care Centre in Chennai, India.
2016
Indian journal of endocrinology and metabolism
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Oral treatment with Eubacterium hallii improves insulin sensitivity in db/db mice.
2016
NPJ biofilms and microbiomes
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Relationship between gut microbiota and type 2 diabetic erectile dysfunction in Sprague-Dawley rats.
2017
Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Gut Microbiome Profiles Are Associated With Type 2 Diabetes in Urban Africans.
2020
Frontiers in cellular and infection microbiology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Dysbiosis and Implication of the Gut Microbiota in Diabetic Retinopathy.
2021
Frontiers in cellular and infection microbiology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Application of machine learning tools: Potential and useful approach for the prediction of type 2 diabetes mellitus based on the gut microbiome profile.
2022
Experimental and therapeutic medicine
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Cardiovascular Benefits of Empagliflozin Are Associated With Gut Microbiota and Plasma Metabolites in Type 2 Diabetes.
2022
The Journal of clinical endocrinology and metabolism
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Polyethylene Glycol Loxenatide Injection (GLP-1) Protects Vascular Endothelial Cell Function in Middle-Aged and Elderly Patients With Type 2 Diabetes by Regulating Gut Microbiota.
2022
Frontiers in molecular biosciences
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Intermittent hypoxia is involved in gut microbial dysbiosis in type 2 diabetes mellitus and obstructive sleep apnea-hypopnea syndrome.
2022
World journal of gastroenterology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Association of gut microbiota and inflammatory markers in obese patients with type 2 diabetes mellitus: post hoc analysis of a synbiotic interventional study.
2022
Bioscience of microbiota, food and health
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Composition and diversity of gut microbiota in diabetic retinopathy.
2022
Frontiers in microbiology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Dynamics of Gut Microbiota and Clinical Variables after Ketogenic and Mediterranean Diets in Drug-Naïve Patients with Type 2 Diabetes Mellitus and Obesity.
2022
Metabolites
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Alterations in the Gut Microbiota in Pregnant Women with Pregestational Type 2 Diabetes Mellitus.
2023
mSystems
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Gut Microbiota and Serum Metabolites in Individuals with Class III Obesity Without Type 2 Diabetes Mellitus: Pilot Analysis.
2023
Metabolic syndrome and related disorders
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Distinct signatures of gut microbiota and metabolites in different types of diabetes: a population-based cross-sectional study.
2023
EClinicalMedicine
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Enhanced trimethylamine metabolism and gut dysbiosis in type 2 diabetes mellitus with microalbumin.
2023
Frontiers in endocrinology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Functional alterations and predictive capacity of gut microbiome in type 2 diabetes.
2023
Scientific reports
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Intestinal Microbiota Composition in Patients with Type 2 Diabetes and Effects of Oral Antidiabetics.
2025
Journal of clinical medicine
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Fecal microbiome analysis in patients with metabolic syndrome and type 2 diabetes.
2025
PeerJ
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.

Supporting primary evidence

2 papers
Effect of metformin and metformin/linagliptin on gut microbiota in patients with prediabetes.
2024
Scientific reports
Human primary paper with plausible association relevance to the disease context.
Systemic and gut microbiome changes with metformin and liraglutide in youth-onset type 2 diabetes: the MIGHTY study.
2025
Gut microbes
Human primary paper with plausible association relevance to the disease context.

Preclinical supporting evidence

16 papers
Subgingival biodiversity in subjects with uncontrolled type-2 diabetes and chronic periodontitis.
2013
Journal of periodontal research
Disease-relevant preclinical or model-based paper useful as supporting evidence.
An Almond-Based Low Carbohydrate Diet Improves Depression and Glycometabolism in Patients with Type 2 Diabetes through Modulating Gut Microbiota and GLP-1: A Randomized Controlled Trial.
2020
Nutrients
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Gut microbiota of patients with type 2 diabetes and gastrointestinal intolerance to metformin differs in composition and functionality from tolerant patients.
2022
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Tang-Ping-San Decoction Remodel Intestinal Flora and Barrier to Ameliorate Type 2 Diabetes Mellitus in Rodent Model.
2022
Diabetes, metabolic syndrome and obesity : targets and therapy
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Analysis of subgingival micro-organisms based on multi-omics and Treg/Th17 balance in type 2 diabetes with/without periodontitis.
2022
Frontiers in microbiology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Lacticaseibacillus rhamnosus Hao9 exerts antidiabetic effects by regulating gut microbiome, glucagon metabolism, and insulin levels in type 2 diabetic mice.
2022
Frontiers in nutrition
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Ethanol extract of propolis regulates type 2 diabetes in mice via metabolism and gut microbiota.
2023
Journal of ethnopharmacology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Influence of Bifidobacterium breve on the Glycaemic Control, Lipid Profile and Microbiome of Type 2 Diabetic Subjects: A Preliminary Randomized Clinical Trial.
2023
Pharmaceuticals (Basel, Switzerland)
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Gut microbiota regulation of inflammatory cytokines and microRNAs in diabetes-associated cognitive dysfunction.
2023
Applied microbiology and biotechnology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Characteristics of intestinal flora in patients with cerebral infarction complicated with Type 2 diabetes mellitus.
2023
Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Roles of gut microbiota in atrial fibrillation: insights from Mendelian randomization analysis and genetic data from over 430,000 cohort study participants.
2023
Cardiovascular diabetology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
A two-sample bidirectional Mendelian randomization analysis investigates associations between gut microbiota and type 2 diabetes mellitus.
2024
Frontiers in endocrinology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Strain-specific gut microbial signatures in type 2 diabetes identified in a cross-cohort analysis of 8,117 metagenomes.
2024
Nature medicine
Disease-relevant preclinical or model-based paper useful as supporting evidence.
The characteristics of intestinal microbiota in patients with type 2 diabetes and the correlation with the percentage of T-helper cells.
2024
Frontiers in microbiology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Anaerobutyricum soehngenii improves glycemic control and other markers of cardio-metabolic health in adults at risk of type 2 diabetes.
2025
Gut microbes
Disease-relevant preclinical or model-based paper useful as supporting evidence.
The mechanism of Gei Herba against type 2 diabetes mellitus: an integration of gut microbiota and network pharmacology analysis.
2026
Artificial cells, nanomedicine, and biotechnology
Disease-relevant preclinical or model-based paper useful as supporting evidence.

Review supporting evidence

5 papers
Gut microbiome and health: mechanistic insights.
2022
Gut
Relevant review or meta-analysis for the signal-disease area.
Gut Microbiota: Therapeutic Targets of Ginseng Against Multiple Disorders and Ginsenoside Transformation.
2022
Frontiers in cellular and infection microbiology
Relevant review or meta-analysis for the signal-disease area.
Dietary intervention improves metabolic levels in patients with type 2 diabetes through the gut microbiota: a systematic review and meta-analysis.
2023
Frontiers in nutrition
Relevant review or meta-analysis for the signal-disease area.
The underlying causes, treatment options of gut microbiota and food habits in type 2 diabetes mellitus: a narrative review.
2024
Journal of basic and clinical physiology and pharmacology
Relevant review or meta-analysis for the signal-disease area.
A novel approach to finding the compositional differences and biomarkers in gut microbiota in type 2 diabetic patients via meta-analysis, data-mining, and multivariate analysis.
2025
Endocrinologia, diabetes y nutricion
Relevant review or meta-analysis for the signal-disease area.